As the European biotech community gears up for one of its most anticipated annual gatherings, Delta4 is pleased to announce its participation in the 26th edition of Bio€quity Europe, taking place May 4 to 6, 2026, in Prague, Czech Republic.
Now in its 26th edition, Bio€quity Europe is the annual European biotech investor conference that brings together CEOs, venture capital firms, and institutional investors to shape the future of life sciences financing on the continent.
This year, the event travels to Central and Eastern Europe for the first time, exploring regional opportunities and debating how European biotech can accelerate to compete and lead in today’s world. Organized by BioCentury and EBD Group, this biotech partnering event has established itself as the leading meeting point for biotech executives and investors, and stands out as the forum that attracts the most venture capital in the European biotech scene.
Building on a Year of Strong Momentum
For Delta4, attendance at Bio€quity Europe represents a natural next step in the company’s growing commercial momentum. After a strong 2025 marked by the successful completion of the FFG-funded Delta4 Tech project, multiple peer-reviewed publications, and expanding roles in the EU Horizon Europe MSCA projects PICKED and PROMOTE, Delta4 enters 2026 with a clear growth agenda: deepening existing pharma relationships, broadening its client base, and raising the profile of the Hyper-C platform with the investment community.
The conference will bring together more than 1,000 executives and investors from over 30 countries, creating an ideal environment for Delta4 to connect with growth-stage biotech companies and biopharma decision-makers who stand to benefit most from AI-driven drug repositioning and indication expansion.
Representing Delta4 in Prague
Representing Delta4 at the event will be Josef Thalmann, who brings strong networking experience and a fresh perspective as Delta4 continues to build out its commercial presence across Europe.
Speed as the Central Theme and Delta4’s Core Proposition
The central theme of this year’s conference is the need for speed in drug development: speed to trials, speed to early human data, and speed to de-risk assets. It is a theme that speaks directly to Delta4’s core value proposition. Through the Hyper-C platform, Delta4 enables pharma and biotech teams to generate mechanistically grounded, data-backed hypotheses in weeks rather than years, helping clients make faster, better-informed decisions about their drug assets.
Looking Ahead
Digital partnering sessions will follow the in-person event on May 12 and 13, 2026, extending the opportunity for connection beyond the Prague Congress Center.
Delta4 looks forward to the conversations ahead and to contributing its perspective on how computational biology and AI can help the European life sciences ecosystem move faster, smarter, and with greater confidence.
